Detailed Analysis of Orthopedic Oncology Market by Diagnostic Imaging, and Bone Biopsy Techniques
The increase in development of targeted therapies and the emergence of novel therapies, surgical techniques, and biomarkers through research and clinical trials will further fuel the growth of the orthopedic oncology market.
According to Future Market Insights research, during the projected period, the global orthopedic oncology market is expected to grow at a CAGR of 6.5%. The market value is projected to increase from US$ 1.2 Billion in 2023 to US$ 2.3 Billion by 2033. The orthopedic oncology market was valued at US$ 1.1 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 7.2% in 2023.
Market Outlook:
Data Points
Market Insights
Market Value 2022
US$ 1.1 Billion
Market Value 2023
US$ 1.2 Billion
Market Value 2033
US$ 2.3 Billion
CAGR 2023 to 2033
6.5%
Market Share of Top 5 Countries
54.1%
Key Market Players
General Electric (GE) Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Hitachi Medical Systems, Hologic, Shimadzu Medical Systems, Carestream Health, Canon Medical Systems, FUJIFILM Medical Systems, Ziehm Imaging, Planmed Oy, EOS imaging, Medtronic plc, Stryker Corporation, Cook Medical, Zimmer Biomet, Biopsybell, Becton Dickenson & Company, and Teleflex Inc.
Orthopedic oncology is a specialized field of medicine which focuses on diagnosing and treatment of bone and soft tissue tumors, both benign and malignant, within the musculoskeletal system. The orthopedic oncology market is driven by multiple factors such as increasing incidences of bone and soft tissue tumours, and advancements in diagnostic techniques and treatment modalities. The field involves orthopedic surgeons, radiologists, and pathologists to give comprehensive care to patients with bone and soft tissue cancer.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of Orthopedic Oncology Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033
The market value for orthopedic oncology was around 0.6% of the overall US$ 191.3 Billion of the global cancer diagnostics market in 2022. The diagnostics of orthopedic oncology expanded at a CAGR of 6.3% from 2017–2022, due to the increasing cases of musculoskeletal cancer.
Orthopedic oncology emerged as a distinct field in the late 1960s and early 1970s when orthopedic surgeons recognized the need for specialized care for patients with bone and soft tissue tumors. The development of advanced imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) scans greatly improved the ability to diagnose and stage tumors accurately, enabling better treatment planning.
Several macroeconomic factors have been affecting the market among which healthcare spending has had a crucial impact on the market.
According to the journal Inquiry 2019, healthcare spending on treatment for cancer has also risen dramatically during the last two decades. Cancer research has resulted in advancements in the early detection and management of cancer during the last several decades, leading to decreases in overall mortality and incidence attributable to cancer.
According to data from the Agency for Healthcare Research and Quality, $57 billion was invested in treatment for cancer in 2001, rising to $88.3 billion in 2011,8 and the National Cancer Institute predicted that national projections of cancer care expenses might reach $173 billion by 2020.
What are the Key Opportunities for the Orthopedic Oncology Manufacturers?
Musculoskeletal tumours represent an uncommon and diverse group of tumours. Sarcomas of the bone and cartilage account for less than one per cent of all cancers in humans. Their prevalence is much higher in youngsters than in adults. The market is affected by the availability of innovative treatment options including targeted therapies and immunotherapies. The number of cancer patients globally is increasing, and technological developments such as image reconstruction programmes, imaging equipment, biomarkers, as well as artificial intelligence algorithms are helping in imaging techniques and surgical techniques are influencing the orthopedic oncology industry.
Techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) scan aid in tumour diagnosis and assessment, while limb-salvage surgeries and reconstructive procedures have improved patients' health. The orthopedic oncology market is likely to expand in the future years, owing to factors such as the rising prevalence of bone and soft tissue tumours, technological developments, and the development of novel treatment options.
Find your sweet spots for generating winning opportunities in this market.
What are the Factors Restraining the Demand for the Orthopedic Oncology?
High treatment expenses, including surgeries, radiation therapy, and chemotherapy, are one of the factors that could limit the growth of the orthopedic oncology market. Patients face financial constraints as a result, limiting their access to effective care, particularly in underdeveloped nations. Another issue will be the scarcity of clinical data and research possibilities. The lack of cutting-edge medicines for patients and poor progress in cancer research impede the development of new treatment choices and creative remedies.
Country-wise Insights
Why is the USA a Prominent Market for Orthopedic Oncology in North America region?
The USA occupies 26.2% share in global market in 2022.
According to the American Cancer Society 2021, Americans are at risk of chondrosarcoma for a variety of causes, including advanced age, enchondroma or multiple enchondromatosis, which is connected to mutations in the IDH1 or IDH2 genes. People who have received radiation therapy (typically to treat another type of cancer) have an increased risk of acquiring bone cancer, according to the Centre for Disease Control and Prevention 2020.
These factors make the USA population more favourable to the orthopedic oncology market. Along with this USA has a well-developed healthcare system with advanced medical infrastructure for the diagnosis and treatment of tumor, thus making the USA a prominent market for orthopedic oncology.
What Makes China a Highly Lucrative Market for Orthopedic Oncology?
China’s revenue generation on orthopedic oncology diagnosis in 2022 was US$ 105.0 Million.
According to Medical Express 2022, In the year 2022, China would have 4.82 million new instances of cancer and 3.21 million deaths due to cancer. The basic occurrence rate for primary bone malignancies was 1.76/100,000 Chinese standard population (ASIRC) as per Clinical Cases in Mineral and Bone Metabolism data from 2012.
China has a strong emphasis on research and development in the field of cancer treatment. As per an article in The Lancet Oncology 2021, The country invests significantly in medical research and clinical trials, and the development of innovative therapies. This focus on research and innovation attracts leading experts and encourages collaboration between the healthcare and pharmaceutical industries. Thus making China a highly lucrative market for orthopedic oncology.
What Makes India a Large Market for Orthopedic Oncology?
In 2022, India held a dominant share of the East Asia market and contributed around US$ 87.9 Million.
The country's rapidly growing economic condition of the middle-class population has increased spending on healthcare and discretionary income. India has a well-developed healthcare system with excellent medical facilities, research institutions, and specialised cancer hospitals.
Recently, in January 2022, Ayushman Bharat approved bone marrow transplants, which are frequently advised to cancer patients. With a population of 1.4 billion, India has a high probability of orthopedic oncology cases. The healthcare scheme is a strength for the population with low socioeconomic backgrounds; as the government of India bears the maximum cost, more and more patients will opt for treatment, resulting in the growth of the orthopedic oncology market in India.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
Why Diagnostics Imaging is Preferred Majorly in Orthopedic Oncology Market?
The market value of diagnostics imaging used for diagnosis is US$ 715.1 Million, representing a sizable 62.3% global market share in 2022. Recently, the Musculoskeletal Tumour Society and the American Academy of Orthopedic Surgeons 2018, agreed upon a clinical practice suggestion titled Use of Imaging before Referral to an orthopedic oncologist.
In the absence of credible data, conventional radiographs are a reasonable diagnostic tool that should be explored during the first evaluation of a soft-tissue tumour. Diagnostics imaging is recommended in orthopedic oncology because it provides precise anatomical details, aids in staging and treatment planning, monitors therapy response and reduces invasiveness and patient pain.
Which Stage of Cancer Will Garner Significant Value Share by 2023?
Stage I of cancer contributes to 36.9% market share in 2022 and is expected to grow with a CAGR of 8.0%. In general, the initial stage of cancer is curable and has a higher possibility of success than the subsequent phases. As a result of the increased emphasis on detection and diagnosis, a greater percentage of patients are recognised and treated in stage I.
Medical technological advancements and growing awareness of the need for early diagnosis have resulted in enhanced screening procedures and increased involvement in cancer screening programmes.
Which Disease Indication is the Most Frequent in Orthopedic Oncology Market?
By indications, osteosarcoma accounted for a predominant share of the global market, with a revenue share of 45.6% in 2022.
According to an article published in Société Internationale de Chirurgie Orthopédique et de Traumatologie 2018, Osteosarcoma (OS) is a type of main malignant bones tumour that affects 3.4 per million individuals globally each year. With an annual incidence of 5.6 cases per million adolescents below the age of 15, OS is the third most frequent cancer during adolescence, after only lymphomas and brain tumours. The greatest prevalence occurs during the second decade of adulthood.
Osteosarcoma was once assumed to be a radioresistant malignancy. However, advances in radiotherapy that makes it possible for the secure delivery of high doses of radiation are encouraging for patients with inoperable or insufficiently resected axial bones. It is aggressive and grows quickly, with an elevated risk and chance of spreading to other regions of the body; hence, it is prevalent in orthopedic oncology.
Which End User is Benefiting the Global Market?
The hospitals have a considerable presence in the orthopedic oncology market, accounting for 48.9% of end users and exhibiting a prominent Compound Annual Growth Rate (CAGR) of 6.0%.
Hospitals are well-equipped with types of equipment and instruments for the diagnosis and treatment of orthopedic cancer. The doctors, nurses and other staff are readily available for treatment and care, and the patient with special care can be admitted to hospital wards. The physicians can observe and treat patients 24*7 in the hospital. Hence these factors make hospitals major benefitting end users in the market.
Competitive Landscape
Collaborations and partnerships among hospitals, healthcare providers, research institutions, and technology businesses can encourage innovation and hasten orthopedic oncology diagnosis and treatment. Many pharmaceutical industries are involved in Research and Development and the development of drugs for the treatment of orthopedic cancer. Among the well-known players in this field are:
Deep learning is being used by the AI-powered platform to boost automation and make MRI scanning more efficient for hospitals dealing with concerns such as staff burnout and rising electricity expenditures.
In November 2022, GE Healthcare launched Ai driven SIGNA Experience platform. With this new technology detection and diagnosis with high accuracy become easy in hospitals.
The research institutions and medical schools have formed an innovative collaboration to advance personalised medicine and provide consumers with high-quality, cost-effective healthcare.
In July 2022, Siemens Healthineers Announces Strategic Partnership with The Ohio State University Wexner Medical Center. The research insights will be shared by the university and with large sponsorship and funding from Siemens Healthineers.
Similarly, recent developments related to the company’s active within the orthopedic oncology market space have been tracked by the team at Future Market Insights, which are available in the full report.
Report Scope as Per Orthopedic Oncology Industry Analysis
Attribute
Details
Forecast Period
2023 to 2033
Historical Data Available for
2017 to 2022
Market Analysis
US$ Million for Value
Key Regions Covered
North America, Latin America, Europe, East Asia, South Asia, Middle East and Africa (MEA)
Key Countries Covered
USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye Northern Africa and South Africa.
Key Market Segments Covered
Diagnostic Techniques, Cancer Stage, Indications, End User, and Region
Key Market Segments Covered in the Orthopedic Oncology Industry Research
By Diagnostic Techniques:
Diagnostic Imaging
X-ray Imaging
MRI Imaging
CT Imaging
PET Imaging
Ultrasound Imaging
Bone Biopsy
Biopsy Needles
Biospy Trays & Kits
By Cancer Stage:
Stage I
Stage II
Stage III
Stage IV
By Indication:
Osteosarcoma
Chondrosarcoma
Ewing Sarcoma
Chordroma
By End User:
Hospitals
Diagnostic Centres
Specialty Orthopedic Clinics
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)
Frequently Asked Questions
What is the market value in 2023?
In 2023, the market is valued US$ 1.2 billion.
What will be the growth rate until 2033?
Until 2033, the market will experience a 6.5% CAGR.
What is majorly propelling the market growth?
Growing prevalence of bone and soft tissue tumors drives market growth.
What is the CAGR for Stage I?
Stage I will expand at an 8.0% CAGR through 2033.
Who are some key market players?
General Electric (GE) Healthcare, Siemens Healthineers, and Koninklijke Philips N.V. are some key players.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Value-Added Insights
4.1. Disease Epidemiology
4.2. Diagnostic Techniques Adoption/Usage Analysis
4.3. Regulatory Landscape, By Country
4.4. Reimbursement Scenario
4.5. Procedure Based Scenarios
4.6. Porter’s Analysis
4.7. PESTLE Analysis
4.8. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Oncology Market Outlook (Parent Market)
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Need for Diagnostic Technique
5.2.2. Increasing Prevalence of Cancer Cases
5.2.3. Growth of Clinical Diagnostics
5.2.4. Technological Advancements in Imaging
5.2.5. New Initiatives For Diagnostic Techniques Development
5.2.6. Cost of Diagnostic Equipment’s
5.2.7. Cost of the Treatment
5.2.8. Research and Development in Cancer Diagnostics
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
6.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Diagnostic Techniques
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Analysis By Diagnostic Techniques, 2017 to 2022
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Diagnostic Techniques, 2023 to 2033
7.3.1. Diagnostic Imaging
7.3.1.1. X-ray Imaging
7.3.1.2. MRI Imaging
7.3.1.3. CT Imaging
7.3.1.4. PET Imaging
7.3.1.5. Ultrasound Imaging
7.3.2. Bone Biopsy
7.3.2.1. Biopsy Needles
7.3.2.2. Biopsy Trays & Kits
7.4. Market Attractiveness Analysis By Diagnostic Techniques
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Cancer Stage
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Cancer Stage, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Cancer Stage, 2023 to 2033
8.3.1. Stage I
8.3.2. Stage II
8.3.3. Stage III
8.3.4. Stage IV
8.4. Market Attractiveness Analysis By Cancer Stage
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
9.3.1. Osteosarcoma
9.3.2. Chondrosarcoma
9.3.3. Ewing Sarcoma
9.3.4. Chordroma
9.4. Market Attractiveness Analysis By Indication
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By End User, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
10.3.1. Hospitals
10.3.2. Diagnostic Centres
10.3.3. Specialty Orthopedic Clinics
10.4. Market Attractiveness Analysis By End User
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) and Forecast By Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. South Asia
11.3.5. East Asia
11.3.6. Oceania
11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. USA
12.3.1.2. Canada
12.3.2. By Diagnostic Techniques
12.3.3. By Cancer Stage
12.3.4. By Indication
12.3.5. By End User
12.4. Market Attractiveness Analysis By Region
12.4.1. By Country
12.4.2. By Diagnostic Techniques
12.4.3. By Cancer Stage
12.4.4. By Indication
12.4.5. By End User
12.5. Market trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. USA Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Diagnostic Techniques
12.8.1.2.2. By Cancer Stage
12.8.1.2.3. By Indication
12.8.1.2.4. By End User
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Diagnostic Techniques
12.8.2.2.2. By Cancer Stage
12.8.2.2.3. By Indication
12.8.2.2.4. By End User
13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Diagnostic Techniques
13.3.3. By Cancer Stage
13.3.4. By Indication
13.3.5. By End User
13.4. Market Attractiveness Analysis By Region
13.4.1. By Country
13.4.2. By Diagnostic Techniques
13.4.3. By Cancer Stage
13.4.4. By Indication
13.4.5. By End User
13.5. Market trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Brazil Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Diagnostic Techniques
13.8.1.2.2. By Cancer Stage
13.8.1.2.3. By Indication
13.8.1.2.4. By End User
13.8.2. Mexico Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Diagnostic Techniques
13.8.2.2.2. By Cancer Stage
13.8.2.2.3. By Indication
13.8.2.2.4. By End User
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Diagnostic Techniques
13.8.3.2.2. By Cancer Stage
13.8.3.2.3. By Indication
13.8.3.2.4. Type By End User
14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. France
14.3.1.3. Spain
14.3.1.4. Russia
14.3.1.5. Italy
14.3.1.6. BENELUX
14.3.1.7. Nordics
14.3.1.8. United Kingdom
14.3.1.9. Rest of Europe
14.3.2. By Diagnostic Techniques
14.3.3. By Cancer Stage
14.3.4. By Indication
14.3.5. By End User
14.4. Market Attractiveness Analysis By Region
14.4.1. By Country
14.4.2. By Diagnostic Techniques
14.4.3. By Cancer Stage
14.4.4. By Indication
14.4.5. By End User
14.5. Market trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Diagnostic Techniques
14.8.1.2.2. By Cancer Stage
14.8.1.2.3. By Indication
14.8.1.2.4. By End User
14.8.2. France Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Diagnostic Techniques
14.8.2.2.2. By Cancer Stage
14.8.2.2.3. By Indication
14.8.2.2.4. By End User
14.8.3. Spain Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Diagnostic Techniques
14.8.3.2.2. By Cancer Stage
14.8.3.2.3. By Indication
14.8.3.2.4. Type By End User
14.8.4. Russia Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Diagnostic Techniques
14.8.4.2.2. By Cancer Stage
14.8.4.2.3. By Indication
14.8.4.2.4. Type By End User
14.8.5. Italy Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Diagnostic Techniques
14.8.5.2.2. By Cancer Stage
14.8.5.2.3. By Indication
14.8.5.2.4. By End User
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Diagnostic Techniques
14.8.6.2.2. By Cancer Stage
14.8.6.2.3. By Indication
14.8.6.2.4. By End User
14.8.7. Nordics Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Diagnostic Techniques
14.8.7.2.2. By Cancer Stage
14.8.7.2.3. By Indication
14.8.7.2.4. By End User
14.8.8. United Kingdom Market Analysis
14.8.8.1. Introduction
14.8.8.2. Market Analysis and Forecast by Market Taxonomy
14.8.8.2.1. By Diagnostic Techniques
14.8.8.2.2. By Cancer Stage
14.8.8.2.3. By Indication
14.8.8.2.4. By End User
15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Thailand
15.3.1.4. Philippines
15.3.1.5. Malaysia
15.3.1.6. Vietnam
15.3.1.7. Rest of South Asia
15.3.2. By Diagnostic Techniques
15.3.3. By Cancer Stage
15.3.4. By Indication
15.3.5. By End User
15.4. Market Attractiveness Analysis By Region
15.4.1. By Country
15.4.2. By Diagnostic Techniques
15.4.3. By Cancer Stage
15.4.4. By Indication
15.4.5. By End User
15.5. Market trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. India Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Diagnostic Techniques
15.8.1.2.2. By Cancer Stage
15.8.1.2.3. By Indication
15.8.1.2.4. By End User
15.8.2. Indonesia Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Diagnostic Techniques
15.8.2.2.2. By Cancer Stage
15.8.2.2.3. By Indication
15.8.2.2.4. By End User
15.8.3. Thailand Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Diagnostic Techniques
15.8.3.2.2. By Cancer Stage
15.8.3.2.3. By Indication
15.8.3.2.4. By End User
15.8.4. Philippines Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Diagnostic Techniques
15.8.4.2.2. By Cancer Stage
15.8.4.2.3. By Indication
15.8.4.2.4. By End User
15.8.5. Malaysia Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Diagnostic Techniques
15.8.5.2.2. By Cancer Stage
15.8.5.2.3. By Indication
15.8.5.2.4. By End User
15.8.6. Vietnam Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Diagnostic Techniques
15.8.6.2.2. By Cancer Stage
15.8.6.2.3. By Indication
15.8.6.2.4. By End User
16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Diagnostic Techniques
16.3.3. By Cancer Stage
16.3.4. By Indication
16.3.5. By End User
16.4. Market Attractiveness Analysis By Region
16.4.1. By Country
16.4.2. By Diagnostic Techniques
16.4.3. By Cancer Stage
16.4.4. By Indication
16.4.5. By End User
16.5. Market trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Diagnostic Techniques
16.8.1.2.2. By Cancer Stage
16.8.1.2.3. By Indication
16.8.1.2.4. By End User
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Diagnostic Techniques
16.8.2.2.2. By Cancer Stage
16.8.2.2.3. By Indication
16.8.2.2.4. By End User
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Diagnostic Techniques
16.8.3.2.2. By Cancer Stage
16.8.3.2.3. By Indication
16.8.3.2.4. By End User
17. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Diagnostic Techniques
17.3.3. By Cancer Stage
17.3.4. By Indication
17.3.5. By End User
17.4. Market Attractiveness Analysis By Region
17.4.1. By Country
17.4.2. By Diagnostic Techniques
17.4.3. By Cancer Stage
17.4.4. By Indication
17.4.5. By End User
17.5. Market trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Diagnostic Techniques
17.8.1.2.2. By Cancer Stage
17.8.1.2.3. By Indication
17.8.1.2.4. By End User
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Diagnostic Techniques
17.8.2.2.2. By Cancer Stage
17.8.2.2.3. By Indication
17.8.2.2.4. By End User
18. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Türkiye
18.3.1.3. South Africa
18.3.1.4. Northern Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Diagnostic Techniques
18.3.3. By Cancer Stage
18.3.4. By Indication
18.3.5. By End User
18.4. Market Attractiveness Analysis By Region
18.4.1. By Country
18.4.2. By Diagnostic Techniques
18.4.3. By Cancer Stage
18.4.4. By Indication
18.4.5. By End User
18.5. Market trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Diagnostic Techniques
18.8.1.2.2. By Cancer Stage
18.8.1.2.3. By Indication
18.8.1.2.4. By End User
18.8.2. Türkiye Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Diagnostic Techniques
18.8.2.2.2. By Cancer Stage
18.8.2.2.3. By Indication
18.8.2.2.4. By End User
18.8.3. South Africa Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Diagnostic Techniques
18.8.3.2.2. By Cancer Stage
18.8.3.2.3. By Indication
18.8.3.2.4. By End User
18.8.4. Northern Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Diagnostic Techniques
18.8.4.2.2. By Cancer Stage
18.8.4.2.3. By Indication
18.8.4.2.4. By End User
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players (%)
19.3. Market Presence Analysis
19.3.1. Regional Footprint of Players
19.3.2. Product Footprint of Players
19.3.3. Channel Footprint of Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Key Development Analysis
20.3. branding and Promotional Strategies, By Key Players
20.4. Competition Deep Dive
20.4.1. General Electric (GE) Healthcare.
20.4.1.1. Overview
20.4.1.2. Product Portfolio
20.4.1.3. Key Financials
20.4.1.4. Sales Footprint
20.4.1.5. Strategy Overview
20.4.1.5.1. Marketing Strategies
20.4.1.5.2. Channel Strategies
20.4.1.5.3. Product Strategies
20.4.2. Siemens Healthineers
20.4.2.1. Overview
20.4.2.2. Product Portfolio
20.4.2.3. Key Financials
20.4.2.4. Sales Footprint
20.4.2.5. Strategy Overview
20.4.2.5.1. Marketing Strategies
20.4.2.5.2. Channel Strategies
20.4.2.5.3. Product Strategies
20.4.3. Koninklijke Philips N.V.
20.4.3.1. Overview
20.4.3.2. Product Portfolio
20.4.3.3. Key Financials
20.4.3.4. Sales Footprint
20.4.3.5. Strategy Overview
20.4.3.5.1. Marketing Strategies
20.4.3.5.2. Channel Strategies
20.4.3.5.3. Product Strategies
20.4.4. Hitachi Medical Systems
20.4.4.1. Overview
20.4.4.2. Product Portfolio
20.4.4.3. Key Financials
20.4.4.4. Sales Footprint
20.4.4.5. Strategy Overview
20.4.4.5.1. Marketing Strategies
20.4.4.5.2. Channel Strategies
20.4.4.5.3. Product Strategies
20.4.5. Hologic
20.4.5.1. Overview
20.4.5.2. Product Portfolio
20.4.5.3. Key Financials
20.4.5.4. Sales Footprint
20.4.5.5. Strategy Overview
20.4.5.5.1. Marketing Strategies
20.4.5.5.2. Channel Strategies
20.4.5.5.3. Product Strategies
20.4.6. Shimadzu Medical Systems
20.4.6.1. Overview
20.4.6.2. Product Portfolio
20.4.6.3. Key Financials
20.4.6.4. Sales Footprint
20.4.6.5. Strategy Overview
20.4.6.5.1. Marketing Strategies
20.4.6.5.2. Channel Strategies
20.4.6.5.3. Product Strategies
20.4.7. Carestream Health
20.4.7.1. Overview
20.4.7.2. Product Portfolio
20.4.7.3. Key Financials
20.4.7.4. Sales Footprint
20.4.7.5. Strategy Overview
20.4.7.5.1. Marketing Strategies
20.4.7.5.2. Channel Strategies
20.4.7.5.3. Product Strategies
20.4.8. Canon Medical Systems
20.4.8.1. Overview
20.4.8.2. Product Portfolio
20.4.8.3. Key Financials
20.4.8.4. Sales Footprint
20.4.8.5. Strategy Overview
20.4.8.5.1. Marketing Strategies
20.4.8.5.2. Channel Strategies
20.4.8.5.3. Product Strategies
20.4.9. FUJIFILM Medical Systems
20.4.9.1. Overview
20.4.9.2. Product Portfolio
20.4.9.3. Key Financials
20.4.9.4. Sales Footprint
20.4.9.5. Strategy Overview
20.4.9.5.1. Marketing Strategies
20.4.9.5.2. Channel Strategies
20.4.9.5.3. Product Strategies
20.4.10. Ziehm Imaging
20.4.10.1. Overview
20.4.10.2. Product Portfolio
20.4.10.3. Key Financials
20.4.10.4. Sales Footprint
20.4.10.5. Strategy Overview
20.4.10.5.1. Marketing Strategies
20.4.10.5.2. Channel Strategies
20.4.10.5.3. Product Strategies
20.4.11. Planmed Oy
20.4.11.1. Overview
20.4.11.2. Product Portfolio
20.4.11.3. Key Financials
20.4.11.4. Sales Footprint
20.4.11.5. Strategy Overview
20.4.11.5.1. Marketing Strategies
20.4.11.5.2. Channel Strategies
20.4.11.5.3. Product Strategies
20.4.12. EOS imaging
20.4.12.1. Overview
20.4.12.2. Product Portfolio
20.4.12.3. Key Financials
20.4.12.4. Sales Footprint
20.4.12.5. Strategy Overview
20.4.12.5.1. Marketing Strategies
20.4.12.5.2. Channel Strategies
20.4.12.5.3. Product Strategies
20.4.13. Medtronic plc
20.4.13.1. Overview
20.4.13.2. Product Portfolio
20.4.13.3. Key Financials
20.4.13.4. Sales Footprint
20.4.13.5. Strategy Overview
20.4.13.5.1. Marketing Strategies
20.4.13.5.2. Channel Strategies
20.4.13.5.3. Product Strategies
20.4.14. Stryker Corporation
20.4.14.1. Overview
20.4.14.2. Product Portfolio
20.4.14.3. Key Financials
20.4.14.4. Sales Footprint
20.4.14.5. Strategy Overview
20.4.14.5.1. Marketing Strategies
20.4.14.5.2. Channel Strategies
20.4.14.5.3. Product Strategies
20.4.15. Cook Medical
20.4.15.1. Overview
20.4.15.2. Product Portfolio
20.4.15.3. Key Financials
20.4.15.4. Sales Footprint
20.4.15.5. Strategy Overview
20.4.15.5.1. Marketing Strategies
20.4.15.5.2. Channel Strategies
20.4.15.5.3. Product Strategies
20.4.16. Zimmer Biomet
20.4.16.1. Overview
20.4.16.2. Product Portfolio
20.4.16.3. Key Financials
20.4.16.4. Sales Footprint
20.4.16.5. Strategy Overview
20.4.16.5.1. Marketing Strategies
20.4.16.5.2. Channel Strategies
20.4.16.5.3. Product Strategies
20.4.17. Biopsybell
20.4.17.1. Overview
20.4.17.2. Product Portfolio
20.4.17.3. Key Financials
20.4.17.4. Sales Footprint
20.4.17.5. Strategy Overview
20.4.17.5.1. Marketing Strategies
20.4.17.5.2. Channel Strategies
20.4.17.5.3. Product Strategies
20.4.18. Becton Dickenson & Company
20.4.18.1. Overview
20.4.18.2. Product Portfolio
20.4.18.3. Key Financials
20.4.18.4. Sales Footprint
20.4.18.5. Strategy Overview
20.4.18.5.1. Marketing Strategies
20.4.18.5.2. Channel Strategies
20.4.18.5.3. Product Strategies
20.4.19. Teleflex Inc.
20.4.19.1. Overview
20.4.19.2. Product Portfolio
20.4.19.3. Key Financials
20.4.19.4. Sales Footprint
20.4.19.5. Strategy Overview
20.4.19.5.1. Marketing Strategies
20.4.19.5.2. Channel Strategies
20.4.19.5.3. Product Strategies
21. Assumptions and Acronyms Used22. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Techniques
Table 02: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Cancer Stage
Table 03: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
Table 04: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 05: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
Table 06: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 07: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Techniques
Table 08: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Cancer Stage
Table 09: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
Table 10: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 11: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 12: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Techniques
Table 13: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Cancer Stage
Table 14: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
Table 15: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 16: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 17: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Techniques
Table 18: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Cancer Stage
Table 19: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
Table 20: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 21: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 22: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Techniques
Table 23: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Cancer Stage
Table 24: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
Table 25: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 26: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 27: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Techniques
Table 28: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Cancer Stage
Table 29: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
Table 30: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 31: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 32: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Techniques
Table 33: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Cancer Stage
Table 34: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
Table 35: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Table 36: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 37: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Diagnostic Techniques
Table 38: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Cancer Stage
Table 39: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
Table 40: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by End User
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) Analysis, 2017 to 2022
Figure 2: Global Market Forecast & Y-o-Y Growth, 2023 to 2033
Figure 3: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2023 to 2033
Figure 4: Global Market Value Share (%) Analysis 2023 and 2033, by Diagnostic Techniques
Figure 5: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Diagnostic Techniques
Figure 6: Global Market Attractiveness Analysis 2023 to 2033, by Diagnostic Techniques
Figure 7: Global Market Value Share (%) Analysis 2023 and 2033, by Cancer Stage
Figure 8: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Cancer Stage
Figure 9: Global Market Attractiveness Analysis 2023 to 2033, by Cancer Stage
Figure 10: Global Market Value Share (%) Analysis 2023 and 2033, by Indication
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Indication
Figure 12: Global Market Attractiveness Analysis 2023 to 2033, by Indication
Figure 13: Global Market Value Share (%) Analysis 2023 and 2033, by End User
Figure 14: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by End User
Figure 15: Global Market Attractiveness Analysis 2023 to 2033, by End User
Figure 16: Global Market Value Share (%) Analysis 2023 and 2033, by Region
Figure 17: Global Market Y-o-Y Growth (%) Analysis 2022 to 2033, by Region
Figure 18: Global Market Attractiveness Analysis 2023 to 2033, by Region
Figure 19: North America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 20: North America Market Value (US$ Million) Forecast, 2023-2033
Figure 21: North America Market Value Share, by Diagnostic Techniques (2023 E)
Figure 22: North America Market Value Share, by Cancer Stage (2023 E)
Figure 23: North America Market Value Share, by Indication (2023 E)
Figure 24: North America Market Value Share, by End User (2023 E)
Figure 25: North America Market Value Share, by Country (2023 E)
Figure 26: North America Market Attractiveness Analysis by Diagnostic Techniques, 2023 to 2033
Figure 27: North America Market Attractiveness Analysis by Cancer Stage, 2023 to 2033
Figure 28: North America Market Attractiveness Analysis by Indication, 2023 to 2033
Figure 29: North America Market Attractiveness Analysis by End User, 2023 to 2033
Figure 30: North America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 31: U.S. Market Value Proportion Analysis, 2022
Figure 32: Global Vs. USA Growth Comparison, 2023 to 2033
Figure 33: USA Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 34: USA Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 35: USA Market Share Analysis (%) by Indication, 2022 & 2033
Figure 36: USA Market Share Analysis (%) by End User, 2022 & 2033
Figure 37: Canada Market Value Proportion Analysis, 2022
Figure 38: Global Vs. Canada. Growth Comparison, 2023 to 2033
Figure 39: Canada Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 40: Canada Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 41: Canada Market Share Analysis (%) by Indication, 2022 & 2033
Figure 42: Canada Market Share Analysis (%) by End User, 2022 & 2033
Figure 43: Latin America Market Value (US$ Million) Analysis, 2017 to 2022
Figure 44: Latin America Market Value (US$ Million) Forecast, 2023-2033
Figure 45: Latin America Market Value Share, by Diagnostic Techniques (2023 E)
Figure 46: Latin America Market Value Share, by Cancer Stage (2023 E)
Figure 47: Latin America Market Value Share, by Indication (2023 E)
Figure 48: Latin America Market Value Share, by End User (2023 E)
Figure 49: Latin America Market Value Share, by Country (2023 E)
Figure 50: Latin America Market Attractiveness Analysis by Diagnostic Techniques, 2023 to 2033
Figure 51: Latin America Market Attractiveness Analysis by Cancer Stage, 2023 to 2033
Figure 52: Latin America Market Attractiveness Analysis by Indication, 2023 to 2033
Figure 53: Latin America Market Attractiveness Analysis by End User, 2023 to 2033
Figure 54: Latin America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 55: Mexico Market Value Proportion Analysis, 2022
Figure 56: Global Vs Mexico Growth Comparison, 2023 to 2033
Figure 57: Mexico Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 58: Mexico Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 59: Mexico Market Share Analysis (%) by Indication, 2022 & 2033
Figure 60: Mexico Market Share Analysis (%) by End User, 2022 & 2033
Figure 61: Brazil Market Value Proportion Analysis, 2022
Figure 62: Global Vs. Brazil. Growth Comparison, 2023 to 2033
Figure 63: Brazil Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 64: Brazil Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 65: Brazil Market Share Analysis (%) by Indication, 2022 & 2033
Figure 66: Brazil Market Share Analysis (%) by End User, 2022 & 2033
Figure 67: Argentina Market Value Proportion Analysis, 2022
Figure 68: Global Vs Argentina Growth Comparison, 2023 to 2033
Figure 69: Argentina Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 70: Argentina Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 71: Argentina Market Share Analysis (%) by Indication, 2022 & 2033
Figure 72: Argentina Market Share Analysis (%) by End User, 2022 & 2033
Figure 73: Europe Market Value (US$ Million) Analysis, 2017 to 2022
Figure 74: Europe Market Value (US$ Million) Forecast, 2023-2033
Figure 75: Europe Market Value Share, by Diagnostic Techniques (2023 E)
Figure 76: Europe Market Value Share, by Cancer Stage (2023 E)
Figure 77: Europe Market Value Share, by Indication (2023 E)
Figure 78: Europe Market Value Share, by End User (2023 E)
Figure 79: Europe Market Value Share, by Country (2023 E)
Figure 80: Europe Market Attractiveness Analysis by Diagnostic Techniques, 2023 to 2033
Figure 81: Europe Market Attractiveness Analysis by Cancer Stage, 2023 to 2033
Figure 82: Europe Market Attractiveness Analysis by Indication, 2023 to 2033
Figure 83: Europe Market Attractiveness Analysis by End User, 2023 to 2033
Figure 84: Europe Market Attractiveness Analysis by Country, 2023 to 2033
Figure 85: UK Market Value Proportion Analysis, 2022
Figure 86: Global Vs. UK Growth Comparison, 2023 to 2033
Figure 87: UK Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 88: UK Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 89: UK Market Share Analysis (%) by Indication, 2022 & 2033
Figure 90: UK Market Share Analysis (%) by End User, 2022 & 2033
Figure 91: Germany Market Value Proportion Analysis, 2022
Figure 92: Global Vs. Germany Growth Comparison, 2023 to 2033
Figure 93: Germany Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 94: Germany Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 95: Germany Market Share Analysis (%) by Indication, 2022 & 2033
Figure 96: Germany Market Share Analysis (%) by End User, 2022 & 2033
Figure 97: Italy Market Value Proportion Analysis, 2022
Figure 98: Global Vs. Italy Growth Comparison, 2023 to 2033
Figure 99: Italy Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 100: Italy Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 101: Italy Market Share Analysis (%) by Indication, 2022 & 2033
Figure 102: Italy Market Share Analysis (%) by End User, 2022 & 2033
Figure 103: France Market Value Proportion Analysis, 2022
Figure 104: Global Vs France Growth Comparison, 2023 to 2033
Figure 105: France Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 106: France Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 107: France Market Share Analysis (%) by Indication, 2022 & 2033
Figure 108: France Market Share Analysis (%) by End User, 2022 & 2033
Figure 109: Spain Market Value Proportion Analysis, 2022
Figure 110: Global Vs Spain Growth Comparison, 2023 to 2033
Figure 111: Spain Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 112: Spain Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 113: Spain Market Share Analysis (%) by Indication, 2022 & 2033
Figure 114: Spain Market Share Analysis (%) by End User, 2022 & 2033
Figure 115: Russia Market Value Proportion Analysis, 2022
Figure 116: Global Vs Russia Growth Comparison, 2023 to 2033
Figure 117: Russia Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 118: Russia Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 119: Russia Market Share Analysis (%) by Indication, 2022 & 2033
Figure 120: Russia Market Share Analysis (%) by End User, 2022 & 2033
Figure 121: BENELUX Market Value Proportion Analysis, 2022
Figure 122: Global Vs BENELUX Growth Comparison, 2023 to 2033
Figure 123: BENELUX Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 124: BENELUX Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 125: BENELUX Market Share Analysis (%) by Indication, 2022 & 2033
Figure 126: BENELUX Market Share Analysis (%) by End User, 2022 & 2033
Figure 127: Nordics Market Value Proportion Analysis, 2022
Figure 128: Global Vs Nordics Growth Comparison, 2023 to 2033
Figure 129: Nordics Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 130: Nordics Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 131: Nordics Market Share Analysis (%) by Indication, 2022 & 2033
Figure 132: Nordics Market Share Analysis (%) by End User, 2022 & 2033
Figure 133: East Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 134: East Asia Market Value (US$ Million) Forecast, 2023-2033
Figure 135: East Asia Market Value Share, by Diagnostic Techniques (2023 E)
Figure 136: East Asia Market Value Share, by Cancer Stage (2023 E)
Figure 137: East Asia Market Value Share, by Indication (2023 E)
Figure 138: East Asia Market Value Share, by End User (2023 E)
Figure 139: East Asia Market Value Share, by Country (2023 E)
Figure 140: East Asia Market Attractiveness Analysis by Diagnostic Techniques, 2023 to 2033
Figure 141: East Asia Market Attractiveness Analysis by Cancer Stage, 2023 to 2033
Figure 142: East Asia Market Attractiveness Analysis by Indication, 2023 to 2033
Figure 143: East Asia Market Attractiveness Analysis by End User, 2023 to 2033
Figure 144: East Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 145: China Market Value Proportion Analysis, 2022
Figure 146: Global Vs. China Growth Comparison, 2023 to 2033
Figure 147: China Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 148: China Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 149: China Market Share Analysis (%) by Indication, 2022 & 2033
Figure 150: China Market Share Analysis (%) by End User, 2022 & 2033
Figure 151: Japan Market Value Proportion Analysis, 2022
Figure 152: Global Vs. Japan Growth Comparison, 2023 to 2033
Figure 153: Japan Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 154: Japan Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 155: Japan Market Share Analysis (%) by Indication, 2022 & 2033
Figure 156: Japan Market Share Analysis (%) by End User, 2022 & 2033
Figure 157: South Korea Market Value Proportion Analysis, 2022
Figure 158: Global Vs South Korea Growth Comparison, 2023 to 2033
Figure 159: South Korea Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 160: South Korea Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 161: South Korea Market Share Analysis (%) by Indication, 2022 & 2033
Figure 162: South Korea Market Share Analysis (%) by End User, 2022 & 2033
Figure 163: South Asia Market Value (US$ Million) Analysis, 2017 to 2022
Figure 164: South Asia Market Value (US$ Million) Forecast, 2023-2033
Figure 165: South Asia Market Value Share, by Diagnostic Techniques (2023 E)
Figure 166: South Asia Market Value Share, by Cancer Stage (2023 E)
Figure 167: South Asia Market Value Share, by Indication (2023 E)
Figure 168: South Asia Market Value Share, by End User (2023 E)
Figure 169: South Asia Market Value Share, by Country (2023 E)
Figure 170: South Asia Market Attractiveness Analysis by Diagnostic Techniques, 2023 to 2033
Figure 171: South Asia Market Attractiveness Analysis by Cancer Stage, 2023 to 2033
Figure 172: South Asia Market Attractiveness Analysis by Indication, 2023 to 2033
Figure 173: South Asia Market Attractiveness Analysis by End User, 2023 to 2033
Figure 174: South Asia Market Attractiveness Analysis by Country, 2023 to 2033
Figure 175: India Market Value Proportion Analysis, 2022
Figure 176: Global Vs. India Growth Comparison, 2023 to 2033
Figure 177: India Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 178: India Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 179: India Market Share Analysis (%) by Indication, 2022 & 2033
Figure 180: India Market Share Analysis (%) by End User, 2022 & 2033
Figure 181: Indonesia Market Value Proportion Analysis, 2022
Figure 182: Global Vs. Indonesia Growth Comparison, 2023 to 2033
Figure 183: Indonesia Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 184: Indonesia Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 185: Indonesia Market Share Analysis (%) by Indication, 2022 & 2033
Figure 186: Indonesia Market Share Analysis (%) by End User, 2022 & 2033
Figure 187: Malaysia Market Value Proportion Analysis, 2022
Figure 188: Global Vs. Malaysia Growth Comparison, 2023 to 2033
Figure 189: Malaysia Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 190: Malaysia Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 191: Malaysia Market Share Analysis (%) by Indication, 2022 & 2033
Figure 192: Malaysia Market Share Analysis (%) by End User, 2022 & 2033
Figure 193: Thailand Market Value Proportion Analysis, 2022
Figure 194: Global Vs. Thailand Growth Comparison, 2023 to 2033
Figure 195: Thailand Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 196: Thailand Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 197: Thailand Market Share Analysis (%) by Indication, 2022 & 2033
Figure 198: Thailand Market Share Analysis (%) by End User, 2022 & 2033
Figure 199: Philippines Market Value Proportion Analysis, 2022
Figure 200: Global Vs. Philippines Growth Comparison, 2023 to 2033
Figure 201: Philippines Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 202: Philippines Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 203: Philippines Market Share Analysis (%) by Indication, 2022 & 2033
Figure 204: Philippines Market Share Analysis (%) by End User, 2022 & 2033
Figure 205: Vietnam Market Value Proportion Analysis, 2022
Figure 206: Global Vs. Philippines Growth Comparison, 2023 to 2033
Figure 207: Vietnam Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 208: Vietnam Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 209: Vietnam Market Share Analysis (%) by Indication, 2022 & 2033
Figure 210: Vietnam Market Share Analysis (%) by End User, 2022 & 2033
Figure 211: Oceania Market Value (US$ Million) Analysis, 2017 to 2022
Figure 212: Oceania Market Value (US$ Million) Forecast, 2023-2033
Figure 213: Oceania Market Value Share, by Diagnostic Techniques (2023 E)
Figure 214: Oceania Market Value Share, by Cancer Stage (2023 E)
Figure 215: Oceania Market Value Share, by Indication (2023 E)
Figure 216: Oceania Market Value Share, by End User (2023 E)
Figure 217: Oceania Market Value Share, by Country (2023 E)
Figure 218: Oceania Market Attractiveness Analysis by Diagnostic Techniques, 2023 to 2033
Figure 219: Oceania Market Attractiveness Analysis by Cancer Stage, 2023 to 2033
Figure 220: Oceania Market Attractiveness Analysis by Indication, 2023 to 2033
Figure 221: Oceania Market Attractiveness Analysis by End User, 2023 to 2033
Figure 222: Oceania Market Attractiveness Analysis by Country, 2023 to 2033
Figure 223: Australia Market Value Proportion Analysis, 2022
Figure 224: Global Vs. Australia Growth Comparison, 2023 to 2033
Figure 225: Australia Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 226: Australia Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 227: Australia Market Share Analysis (%) by Indication, 2022 & 2033
Figure 228: Australia Market Share Analysis (%) by End User, 2022 & 2033
Figure 229: New Zealand Market Value Proportion Analysis, 2022
Figure 230: Global Vs New Zealand Growth Comparison, 2023 to 2033
Figure 231: New Zealand Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 232: New Zealand Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 233: New Zealand Market Share Analysis (%) by Indication, 2022 & 2033
Figure 234: New Zealand Market Share Analysis (%) by End User, 2022 & 2033
Figure 235: Middle East & Africa Market Value (US$ Million) Analysis, 2017 to 2022
Figure 236: Middle East & Africa Market Value (US$ Million) Forecast, 2023-2033
Figure 237: Middle East & Africa Market Value Share, by Diagnostic Techniques (2023 E)
Figure 238: Middle East & Africa Market Value Share, by Cancer Stage (2023 E)
Figure 239: Middle East & Africa Market Value Share, by Indication (2023 E)
Figure 240: Middle East & Africa Market Value Share, by End User (2023 E)
Figure 241: Middle East & Africa Market Value Share, by Country (2023 E)
Figure 242: Middle East & Africa Market Attractiveness Analysis by Diagnostic Techniques, 2023 to 2033
Figure 243: Middle East & Africa Market Attractiveness Analysis by Cancer Stage, 2023 to 2033
Figure 244: Middle East & Africa Market Attractiveness Analysis by Indication, 2023 to 2033
Figure 245: Middle East & Africa Market Attractiveness Analysis by End User, 2023 to 2033
Figure 246: Middle East & Africa Market Attractiveness Analysis by Country, 2023 to 2033
Figure 247: GCC Countries Market Value Proportion Analysis, 2022
Figure 248: Global Vs GCC Countries Growth Comparison, 2023 to 2033
Figure 249: GCC Countries Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 250: GCC Countries Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 251: GCC Countries Market Share Analysis (%) by Indication, 2022 & 2033
Figure 252: GCC Countries Market Share Analysis (%) by End User, 2022 & 2033
Figure 253: Türkiye Market Value Proportion Analysis, 2022
Figure 254: Global Vs. Türkiye Growth Comparison, 2023 to 2033
Figure 255: Türkiye Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 256: Türkiye Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 257: Türkiye Market Share Analysis (%) by Indication, 2022 & 2033
Figure 258: Türkiye Market Share Analysis (%) by End User, 2022 & 2033
Figure 259: South Africa Market Value Proportion Analysis, 2022
Figure 260: Global Vs. South Africa Growth Comparison, 2023 to 2033
Figure 261: South Africa Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 262: South Africa Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 263: South Africa Market Share Analysis (%) by Indication, 2022 & 2033
Figure 264: South Africa Market Share Analysis (%) by End User, 2022 & 2033
Figure 265: Northern Africa Market Value Proportion Analysis, 2022
Figure 266: Global Vs Northern Africa Growth Comparison, 2023 to 2033
Figure 267: Northern Africa Market Share Analysis (%) by Diagnostic Techniques, 2022 & 2033
Figure 268: Northern Africa Market Share Analysis (%) by Cancer Stage, 2022 & 2033
Figure 269: Northern Africa Market Share Analysis (%) by Indication, 2022 & 2033
Figure 270: Northern Africa Market Share Analysis (%) by End User, 2022 & 2033
